References for Chapter 31 Cardiovascular Drug–Drug Interactions

References for Chapter 31 

Cardiovascular Drug–Drug Interactions 

Angela Cheng-Lai, PharmD 

James J. Nawarskas, PharmD 

William H. Frishman, MD 

1. In sour economy, some scale back on medications. 

New York Times article dated October 21, 2008. 

Available at http://www.nytimes.com/2008/10/22/ 

business/22drug.html. Accessed January 31, 2010. 

2. IMS Health press release dated March 12, 2008. 

Available at: http://www.imshealth.com/portal/ 

site/imshealth/menuitem.a46c6d4df3db4b3d88f61 

1019418c22a/?vgnextoid=280c1d3be7a29110Vgn 

VCM10000071812ca2RCRD&vgnextfmt=default. 

Accessed January 31, 2010. 

3. Lipitor prescribing information. Pfizer Ireland 

Pharmaceuticals. Dublin, Ireland. June 2009. 

4. Hansten P, Horn J. Drug-drug interaction mechanisms. 

Available at: http://hanstenandhorn.com/ 

article-d-i.html. Accessed January 31, 2010. 

5. Chang GW, Kam PC. The physiological and pharmacological 

roles of cytochrome P450 isoenzymes. 

Anaesthesia 54:42, 1999. 

6. Michalets EL. Update: Clinically significant cytochrome 

P-450 drug interactions. Pharmacotherapy 

18:84, 1998. 

7. Horn JR, Hansten PD. Get to know an enzyme: 

CYP3A4. Pharmacy Times 2008;9:40. Available at: 

http://www.pharmacytimes.com/issue/pharmacy/2008/2008-09/2008-09-8687. 

Accessed January 

31, 2010. 


CYP1A2. Pharmacy Times 2007;11:76. Available 

at: http://www.pharmacytimes.com/issue/pharmacy/2007/2007-11/2007-11-8279. 




CYP2C19. Pharmacy Times 2008;5:32. Available 

at: http://www.pharmacytimes.com/issue/pharmacy/2008/2008-05/2008-05-8538. 




CYP2C9. Pharmacy Times 2008;3:37. Available at: 





CYP2D6. Pharmacy Times 2008;7:32. Available at: 




12. Anderson JR, Nawarskas JJ. Cardiovascular drugdrug 

interactions. Cardiology Clinics 19:215, 2001. 

13. Hansten PD, Horn JR, eds. Hansten and Horn’s 

Drug Interactions Analysis and Management. St. 

Louis, MO, Facts & Comparisons, 2009. 

14. Bigger JT Jr. Leahey EB Jr. Quinidine and digoxin: 

an important interaction. Drugs 24:229, 1982. 

15. Schenck-Gustafsson K, Juhlin-Dannfelt A, 

Dahlqvist R. Renal function and digoxin clearance 

during quinidine therapy. Clinical Physiology 2:401, 

1982. 

16. Horn JR, Hansten PD. Drug transporters: the final 

frontier for drug interactions. Pharmacy Times 

12:28, 2008. 

17. Horn JR, Hansten PD. Drug transporters: the final 

frontier for drug interactions – part 2. Pharmacy 

Times 2:33, 2009. 

18. Eberl S, Renner B, Neubert A, et al. Role of P-glycoprotein 

inhibition for drug interactions. Clin Pharmacokinet. 

46:1039, 2007. 

19. Rengelshausen J, Goggelmann C, Burhenne J, et al. 

Contribution of increased oral bioavailability and 

reduced nonglomerular renal clearance of digoxin 

to the digoxin-clarithromycin interaction. Br J Clin 

Pharmacol. 56:32, 2003. 

20. Gurley BJ, Swain A, Williams DK, et al. Gauging 

Cardiovascular Pharmacotherapeutics, 3rd ed. © 2011 William H. Frishman and Domenic A. Sica, eds. Cardiotext Publishing, ISBN: 

978-0-9790164-3-1. 

31-1

31-2 Cardiovascular Pharmacotherapeutics 

the clinical significance of P-glycoprotein-mediated 

herb-drug interactions: comparative effects 

of St. John’s wort, Echinacea, clarithromycin, and 

rifampin on digoxin pharmacokinetics. Mol Nutr 

Food Res. 52:772, 2008. 

21. Regazzi MB, Iacona I, Campana C, et al. Altered 

disposition of pravastatin following concomitant 

drug therapy with cyclosporin A in transplant recipients. 

Transplant Proc. 25:2732, 1993. 

22. Somogyi A, McLean A, Heinzow B. Cimetidineprocainamide 

pharmacokinetic interaction in 

man: evidence of competition for tubular secretion 

of basic drugs. Eur J Clin Pharmacol. 25:339, 1983. 

23. Micromedex Healthcare series, (electronic version). 

Thomson Micromedex, Greenwood Village, 

Colorado, USA. Available at: http://www.thomsonhc.com. 

Assessed: 1/30/2010. 

24. Quinn DI, Day RO. Drug interactions of clinical 

importance. An updated guide. Drug Safety 12: 

393, 1995. 

25. Mignat C, Unger T. ACE inhibitors. Drug interactions 

of clinical significance. Drug Safety 12: 334, 

1995. 

26. Salvetti A, Abdel-Haq B, Magagna A, et al. Indomethacin 

reduces the antihypertensive action of 

enalapril. Clin Exp Hypertens A. 9:559, 1987. 

27. Abdel-Haq B, Magagna A, Favilla S, et al. Hemodynamic 

and humoral interactions between perindopril 

and indomethacin in essential hypertensive 

subjects. J Cardiovasc Pharmacol. 18 (Suppl 7):S33, 

1991. 

28. Seelig CB, Maloley PA, Campbell JR, et al. Nephrotoxicity 

associated with concomitant ACE inhibitor 

and NSAID therapy. South Med J. 83:1144, 1990. 

29. Stys T, Lawson WE, Smaldone GC, et al. Does aspirin 

attenuate the beneficial effects of angiotensinconverting 

enzyme inhibition in heart failure? Arch 

Intern Med. 160:1409, 2000. 

30. Nguyen KN, Aursnes I, Kjekshus J. Interaction between 

enalapril and aspirin on mortality after acute 

myocardial infarction: subgroup analysis of the 

Cooperative New Scandinavian Enalapril Survival 

Study II (CONSENSUS II). Am J Cardiol. 79:115, 

1997. 

31. Al-Khadra AS, Salem DN, Rand WM, et al. Antiplatelet 

agents and survival: a cohort analysis from 

the studies of left ventricular dysfunction (SOLVD) 

trial. J Am Coll Cardiol. 31:419, 1998. 

32. Oosterga M, Anthonio RL, de Kam PJ, et al. Effects 

of aspirin on angiotensin-converting enzyme inhibition 

and left ventricular dilation one year after 

acute myocardial infarction. Am J Cardiol. 81:1178, 

1998. 

33. Weksler BB, Pett SB, Alonso D, et al. Differential 

inhibition by aspirin of vascular and platelet prostaglandin 

synthesis in atherosclerotic patients. N 

Engl J Med. 308:800, 1983. 

34. Arauz-Pacheco C, Ramirez LC, Rios JM, et al. Hypoglycemia 

induced by angiotensin-converting 

enzyme inhibitors in patients with non-insulindependent 

diabetes receiving sulfonylurea therapy. 

The American Journal of Medicine. 89:811, 1990. 

35. Ahmad S. Drug interaction induces hypoglycemia. 

J Fam Pract. 40:540, 1995. 

36. Page RL II, Miller GG, Lindenfeld J. Drug therapy 

in the heart transplant recipient. Part IV: Drug- 

Drug interactions. Circlation. 111:230, 2005. 

37. Gossmann J, Thürmann P, Bachmann T, et al. 

Mechanism of angiotensin converting enzyme 

inhibitor-related anemia in renal transplant recipients. 

Kidney Int. 50:973, 1996. 

38. Gossmann J, Kachel HG, Schoeppe W, et al. 

Anemia in renal transplant recipients caused by 

concomitant therapy with azathioprine and angiotensin-converting 

enzyme inhibitors. Transplantation. 

56:585, 1993. 

39. Ahmad S. Allopurinol and enalapril. Drug induced 

anaphylactic coronary spasm and acute myocardial 

infarction. Chest. 108:586, 1995. 

40. Pennell DJ, Nunan TO, O’Doherty MJ, et al. Fatal 

Stevens-Johnson syndrome in a patient on captopril 

and allopurinol. Lancet. 1:463, 1984. 

41. Samanta A, Burden AC. Fever, myalgia, and arthralgia 

in a patient on captopril and allopurinol. 

Lancet. 1:679, 1984. 

42. Murray BM, Venuto RC, Kohli R, et al. Enalaprilassociated 

acute renal failure in renal transplants: 

possible role of cyclosporine. Am J Kidney Dis. 

16:66, 1990. 

43. Douste-Blazy P, Rostin M, Livarek B, et al. Angiotensin 

converting enzyme inhibitors and lithium 

treatment. Lancet. 1:1448, 1986. 

44. Correa FJ, Eiser AR. Angiotensin-converting enzyme 

inhibitors and lithium toxicity. Am J Med. 

93:108, 1992. 

45. Baldwin CM, Safferman AZ. A case of lisinoprilinduced 

lithium toxicity. DICP. 24:946, 1990. 

46. Unger T, Kaschina E. Drug interactions with angiotensin 

receptor blockers: A comparison with other 

antihypertensives. Drug Safety 26:707, 2003. 

47. Böhler S, Pittrow D, Bramlage P, et al. Drug interactions 

with angiotensin receptor blockers. Expert 

Opin. Drug Saf. 4:7, 2005. 

48. Kazierad DJ, Martin DE, Blum RA, et al. Effect of 

fluconazole on the pharmacokinetics of eprosartan 

and losartan in healthy male volunteers. Clin Pharmacol 

Ther. 62:417, 1997. 

49. Williamson KM, Patterson JH, McQueen RH, et

References to Chapter 31 31-3 

al. Effects of erythromycin or rifampin on losartan 

pharmacokinetics in healthy volunteers. Clin Pharmacol 

Ther. 63:316, 1998. 

50. Marino MR, Vachharajani NN. Drug interactions 

with irbesartan. Clin Pharmacokinet. 40:605, 2001. 

51. Mangold B, Gielsdorf W, Marino MR. Irbesartan 

does not affect the steady-state pharmacodynamics 

and pharmacokinetics of warfarin. Eur J Clin Pharmacol. 

55:593, 1999. 

52. Trujillo TC, Nolan PE. Antiarrhythmic agents. 

Drug interactions of clinical significance. Drug 

Safety 23:509, 2000. 

53. Spinler SA, Cheng JW, Kindwall KE, et al. Possible 

inhibition of hepatic metabolism of quinidine by 

erythromycin. Clin Pharmacol Ther. 57:89, 1995. 

54. Yamreudeewong W, DeBisschop M, Martin LG, et 

al. Potentially significant drug interactions of class 

III antiarrhythmic drugs. Drug Safety 26:421, 2003. 

55. Bailey DG, Dresser GK. Interactions between 

grapefruit juice and cardiovascular drugs. Am J 

Cardiovasc Drugs 4:281, 2004. 

56. Kappenberger TR, Steinbrunn W, Meyer UA. Dangerous 

interactions between amiodarone and quinidine. 

Lancet. 1:1327, 1982. 

57. Baker BJ, Gammill J, Massengill J, et al. Concurrent 

use of quinidine and disopyramide: evaluation of 

serum concentrations and electrocardiographic effects. 

Am Heart J. 105:12, 1983. 

58. Hughes B, Dyer JE, Schwartz AB. Increased procainamide 

plasma concentrations caused by quinidine: 

a new drug interaction. Am Heart J. 114(4 Pt 

1):908, 1987. 

59. Saal AK, Werner JA, Greene HL, et al. Effect of 

amiodarone on serum quinidine and procainamide 

levels. Am J Cardiol. 53:1264, 1984. 

60. Mörike KE, Roden DM. Quinidine-enhanced beta-blockade 

during treatment with propafenone in 

extensive metabolizer human subjects. Clin Pharmacol 

Ther. 55:28, 1994. 

61. Cooke CE, Sklar GE, Nappi JM. Possible pharmacokinetic 

interaction with quinidine: ciprofloxacin 

or metronidazole? Ann Pharmacother. 30:364, 

1996. 

62. Lin JC, Quasny HA. QT prolongation and development 

of torsades de pointes with the concomitant 

administration of oral erythromycin base and 

quinidine. Pharmacotherapy. 17:626, 1997. 

63. Kaukonen KM, Olkkola KT, Neuvonen PJ. Itraconazole 

increases plasma concentrations of quinidine. 

Clin Pharmacol Ther. 62:510, 1997. 

64. Farringer JA, Green JA, O’Rourke RA, et al. Nifedipine-induced 

alterations in serum quinidine 

concentrations. Am Heart J. 108:1570, 1984. 

65. Data JL, Wilkinson GR, Nies AS. Interaction of 

quinidine with anticonvulsant drugs. N Engl J Med. 

294:699, 1976. 

66. Koch-Weser J. Quinidine-induced hypoprothrombinemic 

hemorrhage in patients on chronic warfarin 

therapy. Ann Intern Med. 68:511, 1968. 

67. Vlasses PH, Kosoglou T, Chase SL, et al. Trimethoprim 

inhibition of the renal clearance of procainamide 

and N-acetylprocainamide. Arch Intern 

Med. 149:1350, 1989. 

68. Rocci ML Jr, Kosoglou T, Ferguson RK, et al. Ranitidine-induced 

changes in the renal and hepatic 

clearances of procainamide are correlated. J Pharmacol 

Exp Ther. 248;923, 1989. 

69. Martin DE, Shen J, Griener J. Effects of ofloxacin 

on the pharmacokinetics and pharmacodynamics 

of procainamide. J Clin Pharmacol. 36:85, 1996. 

70. Bonde J, Bødtker S, Angelo HR, et al. Atenolol inhibits 

the elimination of disopyramide. Eur J Clin 

Pharmacol. 28:41, 1985. 

71. Kapil RP, Axelson JE, Mansfield IL, et al. Disopyramide 

pharmacokinetics and metabolism: effect of 

inducers. Br J Clin Pharmacol. 24:781, 1987. 

72. Ragosta M, Weihl AC, Rosenfeld LE. Potentially 

fatal interaction between erythromycin and disopyramide. 

Am J Med. 86:465, 1989. 

73. Siegmund JB, Wilson JH, Imhoff TE. Amiodarone 

interaction with lidocaine. J Cardiovasc Pharmacol. 

21:513, 1993. 

74. Conrad KA, Byers JM 3rd, Finley PR, et al. Lidocaine 

elimination: effects of metoprolol and of propranolol. 


75. Feely J, Wilkinson GR, McAllister CB, et al. Increased 

toxicity and reduced clearance of lidocaine 

by cimetidine. Ann Intern Med. 96:592, 1982. 

76. Katz A, Buskila D, Sukenik S. Oral mexiletine-theophylline 

interaction. Int J Cardiol. 17:227, 1987. 

77. Tjandra-Maga TB, Van Hecken A, Van Melle P, et 

al. Altered pharmacokinetics of oral flecainide by 

cimetidine. Br. J. Clin. Pharmac. 22:108, 1986. 

78. Spinler SA, Gammaitoni A, Charland SL. Propafenone-theophylline 

interaction. Pharmacotherapy. 

13:68, 1993. 

79. Kates RE, Yee YG, Kirsten EB. Interaction between 

warfarin and propafenone in healthy volunteer 

subjects. Clin Pharmacol Ther. 42:305, 1987. 

80. Rees A, Dalal JJ, Reid PG, et al. Dangers of amiodarone 

and anticoagulant treatment. Br Med J(Clin 

Res Ed). 282:1756, 1981. 

81. Hamer A, Peter T, Mandel WJ, et al. The potentiation 

of warfarin anticoagulation by amiodarone. 

Circulation. 65:1025, 1982. 

82. Leor J, Levartowsky D, Sharon C, et al. Amiodarone 

and beta-adrenergic blockers: an interaction 

with metoprolol but not with atenolol. Am Heart J.


116(1 Pt 1):206, 1988. 

83. Nicolau DP, Uber WE, Crumbley AJ 3rd, et al. 

Amiodarone-cyclosporine interaction in a heart 

transplant patient. J Heart Lung Transplant. 11(3 Pt 

1):564, 1992. 

84. Nademanee K, Kannan R, Hendrickson J, et al. 

Amiodarone-digoxin interaction: clinical significance, 

time course of development, potential 

pharmacokinetic mechanisms and therapeutic implications. 

J Am Coll Cardiol. 4:111, 1984. 

85. Nolan PE Jr, Marcus FI, Karol MD, et al. Effect of 

phenytoin on the clinical pharmacokinetics of amiodarone. 

J Clin Pharmacol. 30:1112, 1990. 

86. Windle J, Prystowsky EN, Miles WM, et al. Pharmacokinetic 

and electrophysiologic interactions 

of amiodarone and procainamide. Clin Pharmacol 

Ther. 41:603, 1987. 

87. Lohman JJ, Reichert LJ, Degen LP. Antiretroviral 

therapy increases serum concentrations of amiodarone. 

Ann Pharmacother 33:645, 1999. 

88. Kerin NZ, Blevins RD, Goldman L, et al. The incidence, 

magnitude, and time course of the amiodarone-warfarin 

interaction. Arch Intern Med. 

148:1779, 1988. 

89. Abel S, Nichols DJ, Brearley CJ, et al. Effect of cimetidine 

and ranitidine on pharmacokinetics and 

pharmacodynamics of a single dose of dofetilide. 

Br J Clin Pharmacol. 49:64, 2000. 

90. Garcia D, Cheng-Lai A. Dronedarone. A new antiarrhythmic 

agent for the treatment of atrial fibrillation. 

Cardiology in Review 17:230, 2009. 

91. Elliott HL, McLean K, Summer DJ, et al. Immediate 

cardiovascular responses to oral prazosin-effects 

of concurrent beta-blockers. Clin Pharmacol 

Ther. 29:303, 1981. 

92. Singh S, Saini RK, DiMarco J, et al. Efficacy and 

safety of sotalol in digitalized patients with chronic 

atrial fibrillation. The sotalol study group. Am J 

Cardiol. 68:1227, 1991. 

93. Frishman WH, Cheng-Lai A, Nawarska J (eds): 

Current Cardiovascular Drugs, 4th ed. Philadelphia: 

Current Medicine, 2005. 

94. Harder S, Thürmann P. Clinically important drug 

interactions with anticoagulants. An update. Clin. 

Pharmacokinet. 30:416, 1996. 

95. Chesebro JH, Fuster V, Elveback LR, et al. Trial of 

combined warfarin plus dipyridamole or aspirin 

therapy in prosthetic heart valve replacement: danger 

of aspirin compared with dipyridamole. Am J 

Cardiol. 51:1537, 1983. 

96. Jähnchen E, Meinertz T, Gilfrich HJ, et al. Enhanced 

elimination of warfarin during treatment 

with cholestyramine. Br J Clin Pharmacol. 5:437, 

1978. 

97. Rindone JP, Keng HC. Gemfibrozil-warfarin drug 

interaction resulting in profound hypoprothrombinemia. 

Chest. 114:641, 1998. 

98. O’Reilly RA. Interaction of chronic daily warfarin 

therapy and rifampin. Ann Intern Med. 83:506, 

1975. 

99. Bachmann K, Schwartz JI, Forney R Jr, et al. The effect 

of erythromycin on the disposition kinetics of 

warfarin. Pharmacology. 28:171-6, 1984. 

100. Kazmier FJ. A significant interaction between metronidazole 

and warfarin. Mayo Clin Proc. 51:782, 

1976. 

101. O’Reilly RA. The steroselective interaction of warfarin 

and metronidazole in man. N Engl J Med. 

295:354, 1976. 

102. Gericke KR. Possible interaction between warfarin 

and fluconazole. Pharmacotherapy. 13:508, 1993. 

103. Smith AG. Potentiation of oral anticoagulants by 

ketoconazole. Br Med J (Clin Res Ed). 288:188, 

1984. 

104. Hassall C, Feetam CL, Leach RH, et al. Letter: Potentiation 

of warfarin by co-trimoxazole. Lancet. 

2:1155, 1975. 

105. Singleton JD, Conyers L. Warfarin and azathioprine: 

an important drug interactions. Am J Med. 

92:217, 1992. 

106. Levine M, Sheppard I. Biphasic interaction of phenytoin 

with warfarin. Clin Pharm. 3:200, 1984. 

107. Khalique SC, Cheng-Lai A. Drug interaction between 

clopidogrel and proton pump inhibitors. 

Cardiology in Review 17:198, 2009. 

108. Ho PM, Maddox TM, Wang L, et al. Risk of adverse 

outcomes associated with concomitant use of 

clopidogrel and proton pump inhibitors following 

acute coronary syndrome. JAMA 301:937, 2009. 

109. Juurlink DN, Gomes T, Ko DT, et al. A populationbased 

study of the drug interaction between proton 

pump inhibitors and clopidogrel. CMAJ 180:713, 

2009. 

110. Stanek EJ, Aubert RE, Flockhart DA, et al. A national 

study of the effect of individual proton pump 

inhibitors on cardiovascular outcomes in patients 

treated with clopidogrel following coronary stenting: 

The Clopidogrel Medco Outcomes Study. 

http://www.scai.org/pdf/20090506Medcoabstract. 

pdf (Abstract). 

111. O’Donoghue ML, Braunwald E, Antman EM, et 

al. Pharmacodynamic effect and clinical efficacy 

of clopidogrel and prasugrel with or without a proton-pump 

inhibitor: an analysis of two randomized 

trials. Lancet. 374:989, 2009. 

112. Rassen JA, Choudhry NK, Avorn J, et al. Cardiovascular 

outcomes and mortality in patients using 

clopidogrel with proton pump inhibitors after per-

References to Chapter 31 31-5 

cutaneous coronary intervention or acute coronary 

syndrome. Circulation. 120:2322, 2009. 

113. Information for Healthcare Professionals: Update 

to the labeling of clopidogrel bisulfate (marketed 

as Plavix) to alert healthcare professionals about 

a drug interaction with omeprazole (marketed as 

Prilosec and Prilosec OTC). http://www.fda. 

gov/Drugs/DrugSafety/PostmarketDrugSafety- 

InformationforPatientsandPrescribers Assessed: 

1/18/2010. 

114. Juurlink DN. Proton pump inhibitors and clopidogrel. 

Putting the interaction in perspective. Circulation. 

120:2310, 2009. 

115. Laine L, Hennekens C. Proton pump inhibitor and 

clopidogrel interaction: fact or fiction? Am J Gastroenterol 

105:34, 2010. 

116. Blaufarb I, Pfeifer TM, Frishman WH. b-Blockers. 

Drug interactions of clinical significance. Drug 

Safety 13:359, 1995. 

117. Findlay IN, McInnes GT, Dargie HJ. Beta blockers 

and verapamil: a cautionary tale. Br Med J (Clin Res 

Ed). 289:1074, 1984. 

118. Benaim ME. Asystole after verapamil. Br Med J. 

2:169, 1972. 

119. Hunt BA, Bottorff MB, Herring VL, et al. Effects of 

calcium channel blockers on the pharmacokinetics 

of propranolol stereoisomers. Clin Pharmacol Ther. 

47(5):584, 1990. 

120. Bailey RR, Neale TJ. Rapid clonidine withdrawal 

with blood pressure overshoot exaggerated by beta-blockade. 

Br Med J. 1:942, 1976. 

121. Deacon CS, Bax LNDS, Woods HF, et al. Inhibition 

of oxidative drug metabolism by b-adrenoceptor 

antagonists is related to their lipid solubility. Br J 

Clin Pharmac 12:429, 1981. 

122. Silver JM, Yudofsky SC, Kogan M, et al. Elevation 

of thioridazine plasma levels by propranolol. Am J 

Psychiatry. 143;1290, 1986. 

123. Wagner F, Kalusche D, Trenk D, et al, Drug interaction 

between propafenone and metoprolol. Br J 

Clin Pharmacol. 24:213, 1987. 

124. Kowey PR, Kirsten EB, Fu CH, et al. Interaction 

between propranolol and propafenone in healthy 

volunteers. J Clin Pharmacol. 29:512, 1989. 

125. Schneck DW, Luderer JR, Davis D, et al. Effects of 

nadolol and propranolol on plasma lidocaine clearance. 


126. Walley T, Pirmohamed M, Proudlove C, et al. Interaction 

of metoprolol and fluoxetine. Lancet. 

341:967, 1993. 

127. Miners JO, Wing LM, Lillywhite KJ, et al. Selectivity 

and dose-dependency of the inhibitory effect of 

propranolol on theophylline metabolism in man. 

Br J Clin Pharmacol. 20:219, 1985. 

128. Rosenthal T, Ezra D. Calcium antagonists. Drug 

interactions of clinical significance. Drug Safety 

13:157, 1995. 

129. Ahmad S. Nifedipine-phenytoin interaction. J Am 

Coll Cardiol. 3:1582, 1984. 

130. Bahls FH, Ozuna J, Ritchie DE. Interactions between 

calcium channel blockers and the anticonvulsants 

carbamazepine and phenytoin. Neurology. 

41:740, 1991. 

131. Sica DA. Interaction of grapefruit juice and calcium 

channel blockers. Am J Hypertens 19:768, 2006. 

132. Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole 

greatly increases plasma concentrations and effects 

of felodipine. Clin Pharmacol Ther. 61:410, 1997. 

133. Azie NE, Brater DC, Becker PA, et al. The interaction 

of diltiazem with lovastatin and pravastatin. 


134. Kantola T, Kivistö KT, Neuvonen PJ. Erythromycin 

and verapamil considerably increase serum simvastatin 

and simvastatin acid concentrations. Clin 

Pharmacol Ther. 64:177, 1998. 

135. Kohlhaw K, Wonigeit K, Frei U, et al. Effect of the 

calcium channel blocker diltiazem on cyclosporine 

A blood levels and dose requirements. Transplant 

Proc. 20(2 Suppl 2):572, 1988. 

136. Lindholm A, Henricsson S. Verapamil inhibits cyclosporine 

metabolism. Lancet 1:1262, 1987. 

137. Pesavento TE, Jones PA, Julian BA, et al. Amlodipine 

increases cyclosporine levels in hypertensive 

renal transplant patients: results of a prospective 

study. J Am Soc Nephrol. 7:831, 1996. 

138. Madsen JK, Jensen JD, Jensen LW, et al. Pharmacokinetic 

interaction between cyclosporine and the 

dihydropyridine calcium antagonist felodipine. Eur 

J Clin Pharmacol. 50:203, 1996. 

139. Bourbigot B, Guiserix J, Airiau J, et al. Nicardipine 

increases cyclosporine blood levels. Lancet. 1:1447, 

1986. 

140. Verschraagen M, Koks CHW, Schellens JHM, et 

al. P-glycoprotein system as a determinant of drug 

interactions: The case of digoxin-verapamil. PharmacoRes 

40:301, 1999. 

141. Rameis H, Magometschnigg D, Ganzinger U, et al. 

The diltiazem-digoxin interaction. Clin Pharmacol 

Ther. 36:183, 1984. 

142. Winship LC, McKenney JM, Wright JT Jr, et al. The 

effect of ranitidine and cimetidine on single-dose 

diltiazem pharmacokinetics. Pharmacotherapy. 

5:16, 1985. 

143. Smith SR, Kendall MJ, Lobo J, et al. Ranitidine and 

cimetidine; drug interactions with single dose and 

steady-state nifedipine administration. Br J Clin 

Pharmacol. 23:311, 1987. 

144. Smith MS, Benyunes MC, Bjornsson TD, et al. In-


fluence of cimetidine on verapamil kinetics and dynamics. 


145. Laganière S, Davies RF, Carignan G, et al. Pharmacokinetic 

and pharmacodynamic interactions 

between diltiazem and quinidine. Clin Pharmacol 

Ther. 60:255, 1996. 

146. Van Lith RM, Appleby DH. Quinidine-nifedipine 

interaction. Drug Intell Clin Pharm. 19:829, 1985. 

147. Trohman RG, Estes DM, Castellanos A, et al. Increased 

quinidine plasma concentrations during 

administration of verapamil: a new quinidineverapamil 

interaction. Am J Cardiol. 57:706, 1986. 

148. Klein HO, Beker B, DiSegni E, et al. Asystole produced 

by the combination of amiodarone and digoxin. 

Am Heart J. 113:399, 1987. 

149. Kounis NG. Asystole after verapamil and digoxin. 

Br J Clin Pract. 34:57, 1980. 

150. Steiness E, Olesen KH. Cardiac arrhythmias induced 

by hypokalaemia and potassium loss during 

maintenance digoxin therapy. Br Heart J. 38:167, 

1976. 

151. Seller RH, Cangiano J, Kim KE, et al. Digitalis 

toxicity and hypomagnesemia. Am Heart J. 79:57, 

1970. 

152. Lindenbaum J, Rund DG, Butler VP Jr, et al. Inactivation 

of digoxin by the gut flora: reversal by 

antibiotic therapy. N Engl J Med. 305:789, 1981. 

153. Magnani B, Malini PL. Cardiac Glycosides. Drug 

interactions of clinical significance. Drug Safety 

12:97, 1995. 

154. Robinson K, Johnston A, Walker S, et al. The digoxin-amiodarone 

interaction. Cardiovasc Drugs Ther. 

3:25, 1989. 

155. Calvo MV, Martin-Suarez A, Martin Luengo C, et 

al. Interaction between digoxin and propafenone. 

Ther Drug Monit. 11:10, 1989. 

156. Guven H, Tuncok Y, Guneri S, et al. Age-related 

digoxin-alprazolam interaction. Clin Pharmacol 

Ther. 54:42, 1993. 

157. Nola GT, Pope S, Harrison DC. Assessment of the 

synergistic relationship between serum calcium 

and digitalis. Am Heart J. 79:499, 1970. 

158. Weeks CE, Conard GJ, Kvam DC, et al. The effect of 

flecainide acetate, a new antiarrhythmic, on plasma 

digoxin levels. J Clin Pharmacol. 26:27, 1986. 

159. Sachs MK, Blanchard LM, Green PJ. Interaction of 

itraconazole and digoxin. Clin Infect Dis. 16:400, 

1993. 

160. Waldorff S, Andersen JD, Heebøll-Nielsen N, et al. 

Spironolactone-induced changes in digoxin kinetics. 


161. Davis A, Day RO, Begg EJ. Interactions between 

non-steroidal anti-inflammatory drugs and antihypertensives 

and diuretics. Aust N Z J Med. 16:537, 

1986. 

162. Finley PR, Warner MD, Peabody CA. Clinical relevance 

of drug interactions with lithium. Clin Pharmacokinet. 

29:172, 1995. 

163. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. The 

ACC/AHA expert consensus document: Use of 

sildenafil (Viagra) in patients with cardiovascular 

disease. J Am Coll Cardiol 33:273, 1999. 

164. Cialis (tadalafil) Tablet [prescribing information]. 

Indianapolis, Indiana: Eli Lilly and Company; 

2010. 

165. Levitra (vardenafil) Tablet [prescribing information]. 

Wayne, NJ: Bayer Health Care Pharmaceuticals 

Inc; 2008. 

166. Brown DD, Juhl RP, Warner SL. Decreased bioavailability 

of digoxin due to hypocholesterolemic 

interventions. Circulation. 58:164, 1978. 

167. Pierce LR, Wysowski DK, Gross TP. Myopathy and 

rhabdomyolysis associated with lovastatin-gemfibrozil 

combination therapy. JAMA. 264:71, 1990. 

168. Tal A, Rajeshawari M, Isley W. Rhabdomyolysis 

associated with simvastatin-gemfibrozil therapy. 

South Med J. 90:546, 1997. 

169. Jacobson TA. Myopathy with statin-fibrate combination 

therapy: clinical considerations. Nat Rev 

Endocrinol. 5:507, 2009. 

170. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis 

with fenofibrate + statin versus gemfibrozil 

+ any statin. Am J Cardiol. 95:120, 2005. 

171. Drug interactions with simvastatin. The Medical 

Letter 50:83, 2008. 

172. Jacobson TA. Comparative pharmacokinetic interaction 

profiles of pravastatin, simvastatin, and atorvastatin 

when coadministered with cytochrome 

P450 inhibitors. Am J Cardiol. 94:1140, 2004. 

173. Frishman WH, Horn J: Statin drug interactions: 

not a class effect. Cardiol in Rev 16: 205, 2008.

References for Chapter 31 Cardiovascular Drug–Drug Interactions

Create successful ePaper yourself

Delete template?

Save as template?